Page 5 - Mark Diagnostics News Today

Vancouver, British Columbia--(Newsfile Corp. - November 25, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy company

DBMR published a research report on “Influenza Testing Market 2021 Industry Analysis, Size, Share, Growth, Trends and Forecast to 2027. Influenza Testing Market report provides analysis of top players in all regions with industry size, growth, technology, market insights, demand, trend, key statistics and industry f...

Vancouver, British Columbia--(Newsfile Corp. - June 1, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce today that its wholly-owned subsidiary

Message : Required fields Vancouver, British Columbia--(Newsfile Corp. - May 31, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") announces that it has changed its auditors from Manning Elliott LLP ("Former Auditor") to PricewaterhouseCoopers LLP ("Successor Auditor"). The Former Auditor resigned as the auditor of the Company effective May 17 th, 2021 and the board of directors of the Company appointed the Successor Auditor effective as of the same date, un...

Share this article Share this article ResearchAndMarkets.coms offering. This first edition report At-Home Testing: COVID-19 Trends and Future Potential provides an overview of trends and developments in the home testing industry for the pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This report covers trends that have occurred since the pandemic was declared in 2020 to the recent present - March 31, 2021. For the purp...

Share: Basel, 22 April 2021 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and GenMark Diagnostics, Inc. today announced that Roches wholly owned subsidiary Geronimo Acquisition Corp. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of GenMark Diagnostics, Inc. (NASDAQ:GNMK) at a price of USD 24.05 per share in cash. The tender offer expired at 12:00 midnight, Eastern Time, at the end of the day on 21 Ap...

(0) Vancouver, British Columbia--(Newsfile Corp. - April 21, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce today the agreement by several long-time strategic accredited investors and insiders to exercise approximately 2,000,000 warrants issued in connection with the Companys private placement of units completed in April 2019, with the warrant exercise price of $0.20 per share. All the warrants were exercised before the warranty matu...

Extended Stay America, Inc. (NASDAQ: STAY)  WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Extended Stay America, Inc. (NASDAQ: STAY) in connection with the proposed acquisition of the company and its paired-share REIT, ESH Hospitality, Inc., by funds managed by Blackstone Real Estate Partners and Starwood Capital Group. Under the terms of the merger agreement, STAY shareholders will receive $19.50 in cash for each s...

GenMark Diagnostics, Inc. (NASDAQ: GNMK)  concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Roche for $24.05 per share in cash.  If you are a GenMark shareholder, .   Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. Shareholders are encouraged to contact the firm free of charge to di...

)  WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Extended Stay America, Inc. (NASDAQ: STAY) in connection with the proposed acquisition of the company and its paired-share REIT, ESH Hospitality, Inc., by funds managed by Blackstone Real Estate Partners and Starwood Capital Group. Under the terms of the merger agreement, STAY shareholders will receive $19.50 in cash for each share of STAY common stock that they hold....